According to Zacks, “Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company’s lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California. “
ATRA has been the topic of several other research reports. Jefferies Group reaffirmed a buy rating and issued a $25.00 price objective on shares of Atara Biotherapeutics in a research note on Tuesday, August 9th. JMP Securities reaffirmed a buy rating on shares of Atara Biotherapeutics in a research note on Saturday, July 9th. Citigroup Inc. lifted their price objective on shares of Atara Biotherapeutics from $8.00 to $10.00 and gave the stock a sell rating in a research note on Friday, August 19th. Finally, Goldman Sachs Group Inc. cut shares of Atara Biotherapeutics from a neutral rating to a sell rating and lowered their price objective for the stock from $23.00 to $16.00 in a research note on Thursday, September 15th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. Atara Biotherapeutics currently has an average rating of Hold and a consensus price target of $26.14.
Atara Biotherapeutics (NASDAQ:ATRA) opened at 15.75 on Monday. The company’s 50-day moving average is $19.73 and its 200 day moving average is $20.25. The firm’s market cap is $453.77 million. Atara Biotherapeutics has a 12 month low of $13.31 and a 12 month high of $40.80.
Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Monday, August 8th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by $0.05. On average, equities research analysts predict that Atara Biotherapeutics will post ($2.85) earnings per share for the current year.
In related news, CEO Isaac E. Ciechanover sold 9,600 shares of the firm’s stock in a transaction that occurred on Thursday, July 21st. The shares were sold at an average price of $22.11, for a total transaction of $212,256.00. Following the completion of the sale, the chief executive officer now directly owns 223,228 shares in the company, valued at $4,935,571.08. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO John Mcgrath sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 12th. The stock was sold at an average price of $17.47, for a total transaction of $87,350.00. Following the sale, the chief financial officer now owns 96,823 shares of the company’s stock, valued at $1,691,497.81. The disclosure for this sale can be found here. 16.10% of the stock is currently owned by company insiders.
Several hedge funds have recently bought and sold shares of ATRA. ProShare Advisors LLC boosted its stake in Atara Biotherapeutics by 4.2% in the second quarter. ProShare Advisors LLC now owns 24,236 shares of the company’s stock valued at $546,000 after buying an additional 980 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Atara Biotherapeutics by 3.1% in the first quarter. JPMorgan Chase & Co. now owns 62,600 shares of the company’s stock valued at $1,191,000 after buying an additional 1,900 shares in the last quarter. BlackRock Advisors LLC boosted its stake in Atara Biotherapeutics by 30.2% in the second quarter. BlackRock Advisors LLC now owns 10,186 shares of the company’s stock valued at $229,000 after buying an additional 2,361 shares in the last quarter. DekaBank Deutsche Girozentrale boosted its stake in Atara Biotherapeutics by 23.7% in the second quarter. DekaBank Deutsche Girozentrale now owns 16,200 shares of the company’s stock valued at $365,000 after buying an additional 3,100 shares in the last quarter. Finally, American International Group Inc. boosted its stake in Atara Biotherapeutics by 30.3% in the second quarter. American International Group Inc. now owns 13,371 shares of the company’s stock valued at $301,000 after buying an additional 3,111 shares in the last quarter. Institutional investors and hedge funds own 75.50% of the company’s stock.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.